Study Evaluating LXR-623 in Healthy Japanese Adults

Phase 1CompletedNCT00385489

Wyeth is now a wholly owned subsidiary of Pfizer

Overview

The purpose of this study is to evaluate the safety of LXR-623 in healthy Japanese subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Healthy

Interventions

LXR-623DRUG

Eligibility

Sex: MALEMin age: 20 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy, Japanese Males aged 20-45 years Exclusion Criteria: * A history or active presence of clinically important medical disease

Locations (1)

Unnamed facility

Toshima-ku, Tokyo, Japan

Outcomes

Primary Outcomes

Safety

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.